Axsome Therapeutics, Inc. (AXSM) Financials
AXSM Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 588.2 million | 397.3 million |
2023-09-30 | 600.9 million | 331.3 million |
2023-06-30 | 611.6 million | 332.8 million |
2023-03-31 | 389.2 million | 277.4 million |
AXSM Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -30.4 million | 18.9 million |
2023-09-30 | -53.9 million | 14.8 million |
2023-06-30 | -55.5 million | 15.9 million |
2023-03-31 | -5.9 million | 12.9 million |
AXSM Net Income
No data available :(
AXSM Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 386.2 million | - | 8.3 million |
2023-09-30 | 416.6 million | - | 8.1 million |
2023-06-30 | 437.1 million | 176.8 million | 7.9 million |
2023-03-31 | 246.5 million | 147.6 million | 108000 |
AXSM Shares Outstanding
AXSM Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 7000 | 30.8 million | 86.8 million | - |
2023-09-30 | 371000 | 28.8 million | 55.1 million | 28.1 million |
2023-06-30 | 133000 | 20.6 million | 52.2 million | 26.7 million |
2023-03-31 | 71000 | 17.8 million | 52.8 million | 21.4 million |
AXSM Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 71.5 million | 7.4 million |
2023-09-30 | 57.8 million | 6.5 million |
2023-06-30 | 46.7 million | 4.6 million |
2023-03-31 | 94.6 million | 7.6 million |
AXSM
Price: $74.80
52 week price:
Earnings Per Share: -5.27 USD
P/E Ratio: -20.31
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 1.9 million
Ebitda: -6.3 millionMarket Capitalization: 3.4 billion